The P-III (HIMALAYA) trial evaluates Imfinzi (1500mg, q4w) + tremelimumab (300mg) vs sorafenib in 1324 patients with HCC regardless of baseline liver functional reserve. The P-III (TOPAZ-1) trial evaluates Imfinzi + CT vs PBO + CT in 685 patients with unresectable advanced or m-BTC irrespective of primary tumor location
The exploratory subgroup analysis showed consistent OS benefits in both trials. In (HIMALAYA) trial, ORR, DoR & tolerability profiles for STRIDE were consistent regardless of ALBI score & liver function was stable over time & the outcomes illustrate the effects of treatment discontinuation & QoL benefits for maintaining patients on treatment with the STRIDE regimen
In (TOPAZ-1) trial, the incidence of grade 3 or 4 AEs & TRAEs were comparable b/w treatment groups
Ref: AstraZeneca | Image: AstraZeneca
